PMID- 17852836
OWN - NLM
STAT- MEDLINE
DCOM- 20080731
LR  - 20171116
IS  - 0036-5513 (Print)
IS  - 0036-5513 (Linking)
VI  - 68
IP  - 2
DP  - 2008
TI  - Butyrylcholinesterase K variants increase the risk of coronary artery disease in 
      the population of western Iran.
PG  - 123-9
AB  - The conflicting results of several studies suggest that there is an association 
      between the butyrylcholinesterase-K variant (BCHE-K, G1615A/Ala539Thr) and the 
      risk of developing coronary artery disease (CAD) in diabetes and non-diabetic 
      subjects. The objective of this study was to determine whether the presence of 
      the BCHE-K variant exacerbates the risk of CAD in patients from western Iran with 
      and without type 2 diabetes mellitus (T2DM). This case-control study comprised 
      464 subjects undergoing their first coronary angiography. They were matched and 
      randomly assigned into four groups: CAD+T2DM+ (CAD/T2DM), CAD+DM(-) (CAD/ND), 
      CAD(-)DM+ (T2DM/NCAD) and CAD(-)DM(-)(control). The BCHE-K variant was detected 
      by PCR-RFLP. The BCHE-K allele frequency in CAD patients with and without T2DM 
      [total CAD (TCAD)] and separately for each group (CAD/T2DM and CAD/ND) was 
      significantly higher than in the control group (21.1 % versus 13.3 % (p = 0.001), 
      22.4 % versus 13.3 % (p = 0.001) and 19.7 % versus 13.3 % (p = 0.015), 
      respectively). The odds ratios (ORs) for the BCHE-K heterozygous and homozygous 
      variants in TCAD subjects were 1.65 (95 % CI 1.17-2.3; p = 0.004) and 4.3 
      (1.05-19.4; p = 0.048); for CAD/T2DM individuals 1.76 (1.2-2.6; p = 0.004) and 
      4.73 (0.96-23.3; p = 0.052); and for CAD/ND patients 1.53 (1.05-2.3; p = 0.029) 
      and 3.88 (0.8-19.7; p = 0.7), respectively. The OR of the BCHE-K allele was found 
      to be 1.74 (1.1-2.4; p = 0.001) in TCAD subjects, 1.87 (1.12-1.48; p = 0.001) in 
      the CAD/T2DM group and 1.59 (1.04-1.4; p = 0.016) in CAD/ND subjects. These data 
      suggest that the BCHE-K allele increases the risk of CAD in the population (with 
      and without DM) in western parts of Iran, and its presence intensifies the risk 
      of CAD in T2DM. The fact that the BCHE-K allele, even in the heterozygous form, 
      exacerbates the risk of CAD in this population, suggests that a specific 
      therapeutic intervention should be considered for this particular group of 
      patients.
FAU - Vaisi-Raygani, A
AU  - Vaisi-Raygani A
AD  - Department of Clinical Biochemistry, Kermanshah University of Medical Sciences, 
      Kermanshah, Iran. vaisira@yahoo.com
FAU - Rahimi, Z
AU  - Rahimi Z
FAU - Entezami, H
AU  - Entezami H
FAU - Kharrazi, H
AU  - Kharrazi H
FAU - Bahrhemand, F
AU  - Bahrhemand F
FAU - Tavilani, H
AU  - Tavilani H
FAU - Rezaei, M
AU  - Rezaei M
FAU - Kiani, A
AU  - Kiani A
FAU - Nomanpour, B
AU  - Nomanpour B
FAU - Pourmotabbed, T
AU  - Pourmotabbed T
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20071121
PL  - England
TA  - Scand J Clin Lab Invest
JT  - Scandinavian journal of clinical and laboratory investigation
JID - 0404375
RN  - 0 (DNA Primers)
RN  - EC 3.1.1.8 (Butyrylcholinesterase)
SB  - IM
MH  - Base Sequence
MH  - Butyrylcholinesterase/genetics/*metabolism
MH  - Coronary Artery Disease/enzymology/*epidemiology
MH  - DNA Primers
MH  - Genotype
MH  - Humans
MH  - Iran/epidemiology
MH  - Polymerase Chain Reaction
MH  - Risk Factors
EDAT- 2007/09/14 09:00
MHDA- 2008/08/01 09:00
CRDT- 2007/09/14 09:00
PHST- 2007/09/14 09:00 [pubmed]
PHST- 2008/08/01 09:00 [medline]
PHST- 2007/09/14 09:00 [entrez]
AID - 781956815 [pii]
AID - 10.1080/00365510701576180 [doi]
PST - ppublish
SO  - Scand J Clin Lab Invest. 2008;68(2):123-9. doi: 10.1080/00365510701576180. Epub 
      2007 Nov 21.